U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06794489) titled 'Longitudinal Biomarkers with Selected Outcome Measures in CMT' on Jan. 20.
Brief Summary: The goal of this study is to better understand the progression of CMT1A and identify risk factors influencing disease course. CMT1A, the most common hereditary peripheral neuropathy, shows high variability in individual phenotypes despite genetic similarity. Key objectives include analyzing determinants of phenotypic expression and documenting symptom variability over five years to capture disease dynamics.
Although incurable, novel CMT therapies are in development. Proving efficacy is challenging due to slow progression and limited sensitive ...